Vallone Carol A 4

What Happened
Carol A. Vallone, a director of Definium Therapeutics (DFTX), received equity awards on 2026-06-11 consisting of two acquisitions: 4,666 shares (award) and 19,188 derivative shares (RSUs), for a total of 23,854 RSUs. Each was granted at $0.00 (no cash paid). These are compensation awards (not open-market purchases or sales).

Key Details

• Transaction date: 2026-06-11; reported on Form 4 filed 2026-06-15 (filed timely).
• Grant amounts and price: 4,666 shares @ $0.00 (acquired); 19,188 derivative RSUs @ $0.00 (acquired). Total = 23,854 RSU-equivalents.
• Shares owned after transaction: not disclosed in the filing.
• Footnotes from the filing:
  • F1: The 19,188 (and/or RSU-related awards) are restricted stock units (RSUs); each RSU converts to one common share when vested. RSUs vest 1/12th of the underlying shares each month, with a possible acceleration to vest immediately prior to the next annual meeting if that meeting occurs before the first anniversary, subject to continued service.
  • F2: The filing also includes a standard vesting note for stock options (1/12th monthly vesting and similar acceleration clause); this report does not show an option exercise or sale by the director.
• No sale/exercise or cashless transaction reported — these are awards only.

Context
RSU grants are a common form of executive and director compensation and represent a future right to receive shares if vesting conditions are met; they are not immediate purchases or sales and don’t by themselves signal a director buying or selling stock. The awards vest over time (monthly) and are contingent on continued service (with a potential acceleration clause tied to the company’s annual meeting).